Tag

Drugsafety

All articles tagged with #drugsafety

health2 years ago•1 min saved

"Chicago Trio Hospitalized, One in Coma, Due to Counterfeit Xanax Overdose"

In Illinois, three young adults were hospitalized with severe medical issues after ingesting counterfeit Xanax pills that contained bromazolam, an unapproved "designer" benzodiazepine. They experienced symptoms such as elevated temperatures, seizures, and myocardial injury, leading to intensive care treatment. Two were discharged with lasting health effects, while the third's condition post-transfer is unknown. The presence of bromazolam in the illicit drug market is rising, with a significant increase in related deaths from 2021 to 2022, as reported by the Illinois Department of Public Health.

via WAND|

##bromazolam #drugsafety

health-and-medicine2 years ago•3 min saved

"Study Reveals GLP-1 Drugs Like Ozempic and Wegovy Unlikely to Raise Suicidal Ideation Risk"

A large study funded by the National Institutes of Health found that users of the diabetes drug Ozempic and the obesity drug Wegovy had a slightly lower risk of suicidal thoughts compared to those not taking these medications. This research comes after concerns were raised by a European drug safety agency regarding potential links between these drugs and suicidal thoughts. The study, which analyzed electronic health records from over 100 million people, did not find an increased risk of suicidal ideation, providing reassurance about the safety of these drugs. However, the study was observational and further research is needed to establish cause and effect. The findings are timely as the European Medicines Agency continues its investigation into the safety of these drugs.

via The New York Times|

##drugsafety #health-and-medicine

health2 years ago•2 min saved

"FDA Probes Ozempic and Similar Drugs for Potential Hair Loss, Suicidal Thoughts Amid Weight-Loss Benefits"

The FDA is reviewing side effects reported with GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy, used for diabetes and weight loss. Side effects under investigation include hair loss, suicidal thoughts, and aspiration. While the FDA has not established a causal relationship between the drugs and these risks, they are assessing the need for regulatory actions such as label changes. Patients are advised to consult healthcare providers about concerns, and the FDA continues to monitor drug safety post-approval. Novo Nordisk and Eli Lilly, manufacturers of these drugs, emphasize patient safety and are cooperating with the FDA.

via KABC-TV|

##diabetesmedication #drugsafety

health-and-medicine2 years ago•3 min saved

"FDA Probes Hair Loss and Mental Health Concerns in Obesity and Diabetes Drug Side Effects"

The FDA is investigating reports of potential serious side effects, including hair loss and suicidal thoughts, associated with the use of Wegovy and similar weight loss drugs. These drugs, which have been effective in clinical trials for obesity treatment, are now under scrutiny for adverse events reported post-approval. While these reports do not establish causation, they have prompted the FDA to consider regulatory actions, which could range from updated drug labeling to more severe restrictions if the risks are found to outweigh the benefits.

via Gizmodo|

##drugsafety #fda

health2 years ago•5 min saved

FDA Probes Reports of Hair Loss, Suicidal Thoughts Linked to Diabetes, Weight-Loss Drugs

The FDA is investigating reports of serious side effects, including hair loss and suicidal thoughts, in individuals using GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy, which are medications for diabetes and weight loss. While these reports have prompted a review, the FDA has not yet established a causal relationship between the drugs and the reported risks. The agency is considering regulatory actions such as label changes or the development of a Risk Evaluation and Mitigation Strategy. Novo Nordisk, the manufacturer of several GLP-1 agonists, has emphasized their commitment to patient safety and is cooperating with the FDA in monitoring the drugs' safety profiles.

via WLWT Cincinnati|

##diabetes #drugsafety

health-and-medicine2 years ago•5 min saved

"Study Finds No Rise in Suicidal Thoughts with Diabetes, Weight Loss Drugs Despite FDA Probe"

The FDA is investigating reports of hair loss and suicidal thoughts among users of GLP-1 receptor agonists, such as Ozempic, Mounjaro, and Wegovy, which are medications for diabetes and weight loss. While these side effects, along with aspiration, have been reported to the FDA Adverse Event Reporting System, the FDA has not yet established a causal relationship between the drugs and the risks. The FDA's ongoing drug safety monitoring may lead to regulatory actions like label changes or the development of a Risk Evaluation and Mitigation Strategy. Novo Nordisk, the manufacturer of several GLP-1 agonists, emphasizes their commitment to patient safety and the importance of using these medications under professional medical care.

via WDSU New Orleans|

##diabetes #drugsafety

health2 years ago•2 min saved

"FDA Investigates Claims of Hair Loss and Suicidal Thoughts Linked to Diabetes, Weight Loss Medications"

The FDA is investigating reports of hair loss and suicidal thoughts among users of GLP-1 receptor agonists, a class of drugs used for diabetes and weight loss, including brands like Ozempic, Mounjaro, and Wegovy. While these side effects have been reported to the FDA's Adverse Event Reporting System, the agency has not yet established a causal relationship between the drugs and the risks. The FDA continues to monitor drug safety post-approval and may take actions such as updating labels or implementing risk strategies if necessary. Novo Nordisk, a manufacturer of these drugs, has stated their commitment to patient safety and ongoing collaboration with the FDA.

via CNN|

##diabetesmedication #drugsafety